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Abstract The concurrent application of subtoxic doses of soluble oligomeric forms of human
amyloid-beta (oAb) and Tau (oTau) proteins impairs memory and its electrophysiological surrogate
long-term potentiation (LTP), effects that may be mediated by intra-neuronal oligomers uptake.
Intrigued by these findings, we investigated whether oAb and oTau share a common mechanism
when they impair memory and LTP in mice. We found that as already shown for oAb, also oTau can
bind to amyloid precursor protein (APP). Moreover, efficient intra-neuronal uptake of oAb and oTau
requires expression of APP. Finally, the toxic effect of both extracellular oAb and oTau on memory
and LTP is dependent upon APP since APP-KO mice were resistant to oAb- and oTau-induced
defects in spatial/associative memory and LTP. Thus, APP might serve as a common therapeutic
target against Alzheimer’s Disease (AD) and a host of other neurodegenerative diseases
characterized by abnormal levels of Ab and/or Tau.
DOI: 10.7554/eLife.26991.001
Introduction
Protein aggregation and deposition have been considered key pathogenetic processes in several
neurodegenerative disorders, including Alzheimer’s Disease (AD), tauopathies, Parkinson’s Disease,
Huntington disease and many others (Shelkovnikova et al., 2012; Takalo et al., 2013). More
recently, soluble small aggregates of these proteins have gained a lot of attention in studies aimed
at understanding the etiopathogenesis of these diseases. This is particularly evident in AD, in which
the abnormal increases of the levels of amyloid-beta (Ab) and Tau proteins and their aggregation
are crucial steps in the chain of events leading to dementia (Irvine et al., 2008; Kopeikina et al.,
2012).
The importance of soluble oligomeric forms of Ab (oAb) and Tau (oTau) has been corroborated
by numerous evidences demonstrating their presence in human cerebrospinal fluid in healthy
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individuals and, in higher amounts, in AD patients (Ho¨ltta¨ et al., 2013; Sengupta et al., 2017). oAb
and oTau are also toxic to cell-to-cell communication, as they disrupt synaptic plasticity, paving the
way to the subsequent cognitive impairment (Selkoe, 2008; Lasagna-Reeves et al., 2012; Fa´ et al.,
2016). Interestingly, we have recently demonstrated that a brief exposure to a combination of sub-
toxic doses of extracellular oAb and oTau dramatically reduces memory and its electrophysiological
surrogate long-term potentiation (LTP) (Fa´ et al., 2016). These findings beg the question of whether
they act through a common pathway when they impair memory and LTP.
Ab and Tau share numerous common biochemical features. Both proteins can form insoluble
deposits: that is, extracellular amyloid plaques due to the accumulation of Ab, and intracellular insol-
uble filaments and neurofibrillary tangles formed by Tau. In addition, Ab and Tau are present as
non-fibrillar soluble monomeric and oligomeric species (Selkoe, 2008; Lasagna-Reeves et al., 2010;
Fa´ et al., 2016). They can be secreted at the synapse in an activity-dependent fashion
(Kamenetz et al., 2003; Pooler et al., 2013; Yamada et al., 2014; Fa´ et al., 2016), and enter neu-
rons (Frost et al., 2009; Lai and McLaurin, 2010; Wu et al. 2013; Fa´ et al., 2016). Moreover, both
Ab and Tau can bind to amyloid precursor protein (APP) (Lorenzo et al., 2000; Van Nostrand
et al., 2002; Shaked et al., 2006; Fogel et al., 2014; Takahashi et al., 2015), a protein with a cen-
tral role in AD pathogenesis that might act as a cell surface receptor (Deyts et al., 2016).
APP, the precursor of Ab, which derives from sequential cleavage of APP by b-secretase (also
known as BACE1) and g-secretase (Cole and Vassar, 2007; De Strooper, 2007), has a central role
in AD pathogenesis and might act as both an Ab precursor and a cell surface receptor (Deyts et al.,
2016). Here we have postulated that oAb and oTau involve APP as a common mechanism of action
when they impair memory and LTP. This has been investigated through a series of experiments in
which we have used APP knock-out (APP-KO) mice and assayed whether suppression of APP func-
tion blocks the deleterious effects of both oAb and oTau onto memory and LTP.
Results
Similar to oAb, oTau binds to APP
APP has been shown to bind both Ab and Tau (Lorenzo et al., 2000; Van Nostrand et al., 2002;
Shaked et al., 2006; Fogel et al., 2014; Takahashi et al., 2015). The interaction between oAb and
APP has been thoroughly investigated in studies demonstrating that different species of Ab (mono-
mers, dimers, oligomers and fibrils) bind to APP (Lorenzo et al., 2000; Van Nostrand et al., 2002;
Shaked et al., 2006; Fogel et al., 2014). However, there is no proof that oTau binds to APP, as pre-
vious studies on Tau-APP binding did not use oligomers but fibrils (Giaccone et al., 1996; Islam and
Levy, 1997; Smith et al., 1995; Takahashi et al., 2015). We therefore decided to investigate
whether the interaction between Tau and APP can be extended to oTau. This was accomplished
through two different approaches. In the first one, we utilized membrane fractions from HEK293 cells
stably transfected with human APP with the Swedish mutation (APPSw) and incubated with/out oTau
derived from recombinant 4R/2N Tau protein. After incubation APP was immuno-precipitated (IP)
and the IPs were tested for oTau binding. As shown in Figure 1A, APP co-IPed oTau. In the second
approach, as an alternative method to analyze protein-protein interaction dependent upon the pres-
ence of endogenous APP, we performed far-WB (fWB) on cultured hippocampal neurons from either
wild type (WT) or APP-KO animals. We found that, in lysates from WT cultures, oTau (used as the
bait protein) was detected at the molecular weight of APP (~110 KDa) by an anti-Tau antibody (Tau
5). Conversely, this band was not observed in lysates from control APP-KO cultures (Figure 1B), sup-
porting the interaction between murine APP and oTau. Collectively, these experiments demonstrate
that oTau is able to bind APP.
Expression of APP is required for efficient intra-neuronal uptake of oAb
and oTau
The similarity between Ab and Tau can be extended to the entrance of their oligomers into neurons
from the extracellular space (Frost et al., 2009; Lai and McLaurin, 2010; Wu et al. 2013; Fa´ et al.,
2016). Given that both Ab and Tau can bind to APP, our next goal was to establish whether APP is
needed for oligomer internalization. To address this issue, we treated cultured hippocampal neurons
obtained from WT and APP-KO mice with either 200 nM oAb labeled with HiLyte Fluor 555
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(oAb 555) or 100 nM oTau labeled with IRIS-5 ester dye (oTau-IRIS5) for 20 min and we studied
their cellular internalization by high-resolution confocal microscopy using an automated algorithm to
detect and count intraneuronal spots. We found that WT neurons internalized much more Ab and
Tau than APP-KO cells. In fact, after extracellular oAb 555 application, a higher percentage of WT
neurons exhibited Ab accumulation compared to APP-KO cultures (Figure 2A). Ab accumulation
was found in 91 ± 3% of WT MAP2-positive cells (Figure 2B, Figure 2—source data 1) and the
mean number of intracellular fluorescent spots/neuron was 5.3 ± 0.4 (Figure 2C, Figure 2—source
data 1). When the same treatment was applied to APP-KO cultures we found that 73 ± 5% of total
cells internalized Ab (Figure 2B, Figure 2—source data 1) and the mean number of fluorescent
spots was 2.9 ± 0.2 (Figure 2C, Figure 2—source data 1). Similar results were obtained when WT
and APP-KO neurons were treated with extracellular oTau-IRIS5 (Figure 2D) which was found in 80 ±
6% of WT cells containing 2.7 ± 0.2 fluorescent spots and in 47 ± 6% of APP-KO neurons exhibiting
1.4 ± 0.1 spots (Figure 2E–F, Figure 2—source data 2). Moreover, to provide a global estimate of
the protein uploading into neurons, we performed quantitative analysis of these data through the
‘internalization index’, which showed a 61% reduction in APP-KO neurons compared to WT cells for
oAb (Figure 2G, Figure 2—source data 3), and a 69% reduction for oTau (Figure 2H, Figure 2—
source data 3). Notably, the amounts of Ab and tau oligomers attached to neuronal surface did not
significantly differ between WT and APP-KO cells. Specifically, fluorescent Ab spots were 6.9 ± 0.5
and 6.5 ± 0.6 for WT and APP-KO, respectively (Figure 2I, Figure 2—source data 4); whereas for
Tau they were 4.3 ± 0.4 and 4.0 ± 0.4, respectively (Figure 2J, Figure 2—source data 4). Collec-
tively, these data show that APP suppression reduces the entrance of extracellular oligomers of both
Ab and Tau into neurons.
Figure 1. APP binds to oTau. (A) WB with anti-Tau antibodies Tau5 showing oTau co-IPed with APP in HEK293
cells stably transfected with human APP with the Swedish mutation. * corresponds to the heavy chain of the
antibody used for IP. (B) Representative data from fWB experiments performed on hippocampal neurons from WT
and APP-KO mice, showing interaction between APP and Tau. Tau binding to APP is demonstrated by the
presence of bands recognized by Tau5 antibodies at 110 KDa (the molecular weight of APP). Tubulin was used as
loading control. n = 3.
DOI: 10.7554/eLife.26991.002
Puzzo et al. eLife 2017;6:e26991. DOI: 10.7554/eLife.26991 3 of 21
Research article Neuroscience
Figure 2. APP suppression reduces internalization of oAb and oTau into neurons. (A) Representative images of cultured hippocampal neurons
(microtubule associated protein-2 (MAP2) positive cells) obtained from either WT or APP-KO mice and treated with 200 nM human oligomeric Ab42
labeled with HiLyteTM Fluor 555 (oAb 555) for 20 min and immunostained for MAP-2. Lower images show different XZ cross-sections from the
acquired confocal Z-stack referring to the dotted lines numbered as 1–3 in each panel. Arrowheads indicate internalized proteins. Scale bars: 10 mm. (B–
Figure 2 continued on next page
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The effect of extracellular oAb onto memory depends upon the
presence of endogenous APP
Neuronal uploading of oAb from the extracellular space reduces LTP (Ripoli et al., 2014), a cellular
surrogate of memory. Interestingly, both associative fear memory and spatial memory, two types of
memory that are altered in AD patients, are impaired by oAb (Puzzo et al., 2014). Thus, these
effects may require intra-neuronal uptake of oAb. Since APP is required for efficient uptake of oAb,
we evaluated the effect of oAb onto two types of memory, assessed through Fear Conditioning and
2 day Radial Arm Water Maze (RAWM), respectively, in the presence or absence of functional APP
expression using 3–4 month-old WT and APP-KO mice. Consisting with previous results
(Fiorito et al., 2013; Watterson et al., 2013), high doses of oAb (200 nM in a final volume of 1 ml,
one injection 20 min prior to the training) infused via bilateral cannulas into the dorsal mouse hippo-
campi, resulted in reduced freezing 24 hr after the electric shock in WT mice (Figure 3A, Figure 3—
source data 1), confirming that contextual fear memory is altered by high amounts of oAb. By con-
trast, in interleaved experiments, memory was spared by the deleterious effects of oAb in APP-KO
mice (Figure 3A, Figure 3—source data 1). Similarly, APP-KO mice that were infused with vehicle
displayed normal memory, as previously shown in KO animals of this age (Senechal et al., 2008)
(Figure 3A, Figure 3—source data 1). We also confirmed that the defect in contextual memory
found in WT mice was due to an oAb-induced hippocampal impairment, whereas cued fear learning,
a type of learning depending upon amygdala function (Phillips and LeDoux, 1992), was not affected
in both WT and APP-KO animals treated with vehicle or oAb (Figure 3B, Figure 3—source data 1).
Moreover, we excluded that the defect was due to deficits in mouse capability to perceive the elec-
tric shock, as sensory threshold assessment did not reveal any difference among the four groups of
mice (Figure 3C, Figure 3—source data 1).
We then evaluated short-term spatial memory with the RAWM. As previously shown
(Watterson et al., 2013), WT mice infused with oAb (200 nM in a final volume of 1 ml, one injection
20 min prior to the first trial of RAWM training in day one and two, bilaterally) made a higher num-
ber of errors than vehicle-infused WT littermates during the second day of RAWM testing
(Figure 3D, Figure 3—source data 2). By contrast, the performance of APP-KO mice, which was
normal when these animals were infused with vehicle, was not affected by the Ab infusion
(Figure 3D, Figure 3—source data 2). Control trials with a visible platform did not show any differ-
ence in speed or latency to reach the platform among the four groups, indicating that oAb infusion
did not affect the motility, vision and motivation of mice during RAWM testing (Figure 3E–F,
Figure 2 continued
C) After 20 min of extracellular oAb 555 application, the percentage of WT neurons exhibiting Ab accumulation was 91 ± 3% of total cells (n = 127) and
the mean number of intracellular fluorescent spots/neuron was 5.3 ± 0.4. When the same treatment was applied to APP-KO cultures we found that 73 ±
5% of total cells internalized Ab (n = 112; t test: t(98) = 2.734; p=0.007 comparing APP-KO vs. WT cells) and a markedly lower mean number of
fluorescent spots (2.9 ± 0.2; t(191) = 4.508; p<0.0001 comparing APP-KO vs. WT cells). (D) Representative images of WT and APP-KO cultured
hippocampal neurons treated with 100 nM IRIS-5-labeled human recombinant oligomeric Tau (oTau-IRIS5) for 20 min. Lower images show different XZ
cross-sections from the acquired confocal Z-stack referring to the dotted lines numbered as 1–3 in each panel. Arrowheads indicate internalized
proteins. Scale bars: 10 mm. (E–F) After 20 min of extracellular Tau-IRIS5, the percentage of WT neurons exhibiting Tau was 80 ± 6% of WT cells (n = 88)
with 2.7 ± 0.2 fluorescent spots, whereas 47 ± 6% of APP-KO neurons showed Tau internalization (n = 84; t(71) = 3.945; p=0.0002) with a mean number of
fluorescent spots equal to 1.4 ± 0.1 (t(92) = 4.331; p<0.0001). (G–H) The ‘internalization index’ shown on the graph was 4.9 ± 0.6 in WT neurons treated
with Ab 555 vs. 1.9 ± 0.2 of APP-KO cells (t(98) = 5.246; p<0.0001), and 2.0 ± 0.3 in WT neurons treated with Tau-IRIS5 vs. 0.6 ± 0.1 of APP-KO cells (t(71)
= 5.013; p<0.0001). (I) Fluorescent Ab spots attached to neuronal surface were 6.9 ± 0.5 and 6.5 ± 0.6 for WT and APP-KO, respectively (t(170) = 0.576;
p=0.56). (J) Fluorescent Tau spots attached to neuronal surface were 4.3 ± 0.4 and 4.0 ± 0.4 for WT and APP-KO, respectively (t(93) = 0.363; p=0.72).
DOI: 10.7554/eLife.26991.003
The following source data is available for figure 2:
Source data 1. Data relating to Figure 2B–C.
DOI: 10.7554/eLife.26991.004
Source data 2. Data relating to Figure 2E–F.
DOI: 10.7554/eLife.26991.005
Source data 3. Data relating to Figure 2G–H.
DOI: 10.7554/eLife.26991.006
Source data 4. Data relating to Figure 2I–J.
DOI: 10.7554/eLife.26991.007
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Figure 3. APP is necessary for extracellular oAb to reduce memory. (A) oAb (200 nM) impaired contextual memory in WT mice, whereas it did not
impair memory in APP-KO mice. n = 11 per condition in this and the following panels. 24 hr: ANOVA F(3,40) = 8.047, p<0.0001; Bonferroni: WT + vehicle
vs. WT + oAb: † p<0.001. (B) Freezing responses before (Pre) and after (Post) the auditory cue were the same among vehicle- and oAb-infused APP-KO
mice as well as vehicle- and oAb-infused WT littermates in the cued conditioning test. ANOVA Pre-Cued: F(3,40) = 0.242, p=0.867; Cued: F(3,40) = 0.372,
p=0.774. (C) No difference was detected among the four groups during assessment of the sensory threshold. ANOVA for repeated measures F(3,40) =
0.626, p=0.602. (D) oAb (200 nM) impaired the RAWM performance in WT mice whereas it did not impair the performance in APP-KO mice. ANOVA for
repeated measures (day 2) F(3,40) = 5.297, p=0.004. WT + vehicle vs. WT + oAb: *p<0.05 for block 8 and 9, and # p<0.0001 for block 10. (E–F) Testing
Figure 3 continued on next page
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Figure 3—source data 2). Moreover, open field testing did not reveal any difference among WT
and APP-KO mice treated with vehicle or oAb, indicating that mouse exploratory behavior, which
might affect animal performance in the memory task, was not affected by treatment or genotype
(Figure 3G–H, Figure 3—source data 3). Collectively, these experiments indicate that the deleteri-
ous effect exerted by oAb on memory is dependent upon the presence of endogenous APP.
The effect of extracellular oTau onto memory depends upon the
presence of endogenous APP
Both associative fear memory and spatial memory are impaired not only by oAb, but also by oTau
(Fa´ et al., 2016). As shown before, oTau binds APP and needs APP for an efficient entrance into
neurons, just like oAb. Thus, we tested if, similar to oAb, exogenous oTau requires APP to alter
memory. As previously demonstrated (Fa´ et al., 2016), oTau infusion (500 nM in a final volume of 1
ml, two injections bilaterally at 180 and 20 min prior to the electric shock for fear conditioning or the
first trial of the RAWM training in day one and two) affected the two forms of memory in WT animals
(Figure 4A, Figure 4—source data 1 and Figure 4D, Figure 4—source data 2). By contrast, APP-
KO mice displayed normal performance when they were infused with oTau both in the fear condi-
tioning and RAWM tests (Figure 4A, Figure 4—source data 1 and Figure 4D, Figure 4—source
data 2). Moreover, we did not observe any behavioral differences between groups of mice tested
for cued conditioning (Figure 4B, Figure 4—source data 1), sensory threshold (Figure, Figure 4—
source data 1), visible platform (Figure 4E and F, Figure 4—source data 2) or open field
(Figure 4G and H, Figure 4—source data 3). Thus, as for oAb, the impairment of memory induced
by oTau was dependent upon the presence of APP.
APP is necessary for extracellular oAb and oTau to reduce LTP
LTP represents a cellular correlate of learning and memory (Bliss and Collingridge, 1993). It is
reduced after treatment with both high amounts of oAb and/or oTau (Fa´ et al., 2016). Hence, we
checked whether APP is needed for oAb and oTau to impair LTP at the CA3-CA1 synapses. Follow-
ing recording of basal synaptic transmission (BST), which did not reveal any difference between WT
and APP-KO slices (Figure 5A, Figure 5—source data 1), slices were perfused with oAb, or oTau,
or vehicle prior to eliciting LTP through a theta-burst stimulation. As previously demonstrated
(Puzzo et al., 2005), perfusion with oAb (200 nM for 20 min before the tetanus) reduced LTP in sli-
ces from WT mice (Figure 5B, Figure 5—source data 2). However, consistent with the behavioral
results, the peptide did not impair LTP in slices from APP-KO littermates (Figure 5B, Figure 5—
source data 2). Similarly, oTau (100 nM for 20 min before tetanus) reduced LTP in WT slices but not
in APP-KO slices (Figure 5C, Figure 5—source data 3).
Next, we checked whether the amyloidogenic processing of APP is required for oAb and oTau
toxicity. This was determined by using mice deficient in BACE1 (Luo et al., 2001). In previous WB
analysis of these mice we had confirmed that they do not express BACE1 protein and have impaired
b-processing of APP (Del Prete et al., 2014). BST recording did not reveal any difference between
WT and BACE1-KO slices (Figure 5D, Figure 5—source data 4). Slices perfusion with oAb (200 nM
Figure 3 continued
with the visible platform task for assessment of visual-motor-motivational deficits did not reveal any difference in average speed [ANOVA: F(3,40) =
0.899, p=0.450] (E), and time to reach the visible platform [ANOVA for repeated measures F(3,40) = 0.05, p=0.985] (F) among the four groups. (G–H)
Open field testing showed a similar percentage of time spent in the center compartment [ANOVA for repeated measures F(3,40) = 0.692 p=0.489] (G)
and the number of entries into the center compartment [ANOVA for repeated measures F(3,40) = 0.332, p=0.802] (H) in vehicle- and oAb-infused APP-
KO mice as well as vehicle- and oAb-infused WT littermates, indicating that they had no differences in exploratory behavior.
DOI: 10.7554/eLife.26991.008
The following source data is available for figure 3:
Source data 1. Data relating to Figure 3A–B–C.
DOI: 10.7554/eLife.26991.009
Source data 2. Data relating to Figure 3D–E–F.
DOI: 10.7554/eLife.26991.010
Source data 3. Data relating to Figure 3G–H.
DOI: 10.7554/eLife.26991.011
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Figure 4. APP is necessary for extracellular oTau to reduce memory. (A) oTau (500 nM) impaired contextual memory in WT mice, whereas it did not
impair contextual memory in APP-KO mice. 24 hr: ANOVA F(3,38) = 18.472, p<0.0001; Bonferroni: WT + vehicle vs. WT + oTau: # p<0.0001. WT +
vehicle: n = 11, WT + oTau: n = 12, APP-KO + vehicle: n = 8, APP-KO + oTau: n = 11. (B) Freezing responses before (Pre) and after (Post) the auditory
cue were the same among the four groups shown in A in the cued conditioning test. ANOVA Pre-cued: F(3,38) = 0.215, p=0.885; Cued: F(3,38) = 0.410,
p=0.747. (C) No difference was detected among the four groups shown in A during assessment of the sensory threshold. ANOVA for repeated
measures F(3,38) = 0.643, p=0.592. (D) oTau (500 nM) impaired the RAWM performance in WT mice whereas it did not impair the performance in APP-
Figure 4 continued on next page
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for 20 min before the tetanus), or oTau (100 nM for 20 min before tetanus), or vehicle showed that,
similar to WT mice, oAb and oTau reduced LTP in slices from BACE1-KO mice (Figure 5E, Figure 5—
source data 5 and Figure 5F, Figure 5—source data 6). Thus, these experiments demonstrate that
APP processing is not involved in the toxicity of extracellularly-applied Ab and Tau.
Finally, we asked whether the APP-dependence for the negative effects of oAb and oTau onto
LTP is specific to these oligomers, or a broader property of APP with b-sheet, oligomer forming pro-
teins. To address this question, we selected human amylin (Amy), an amyloid protein of 37 amino-
acids differing from Ab42 in its primary sequence, but sharing with it the ability to form b-sheets and
oligomerize (Wineman-Fisher et al., 2016). Amy crosses the blood brain barrier (Banks et al.,
1995), and has a profile of neurotoxicity that is strikingly similar to that of Ab (Jhamandas et al.,
2011), including the marked reduction of LTP (Kimura et al., 2012). As previously demonstrated
(Kimura et al., 2012), perfusion of hippocampal slices for 20 min with 200 nM oligomeric Amy
(oAmy) produced a marked reduction of LTP in WT slices (Figure 5G, Figure 5—source data 7).
The same impairment of LTP was observed in slices from APP-KO mice (Figure 5G, Figure 5—
source data 7); thus, different than oTau and oAb, oAmy does not require APP for its negative
effect on synaptic plasticity. Collectively, these experiments suggest that a brief exposure to both
oAb or oTau, but not oAmy, needs the presence of endogenous APP to impair LTP.
Discussion
Protein aggregate accumulation in the brain is a common feature to neurodegenerative diseases,
each disease displaying specific aggregating proteins and aggregate distribution. Oligomers of
these proteins are gaining a lot of attention because they are likely to be involved in the cell-to-cell
propagation of the pathology, and look more acutely toxic than large insoluble aggregates. For
instance, in AD, oligomers of both Ab and Tau have been shown to produce an immediate reduction
of synaptic plasticity and memory when extracellularly applied (Fa´ et al., 2016). Intriguingly, the
negative effects of oAb and oTau occurred not only with high concentrations of Ab or Tau alone,
but also when sub-toxic doses of oAb were combined with sub-toxic doses of oTau (Fa´ et al., 2016).
These observations inspired the experiments shown in this manuscript. Here, we demonstrate that
the suppression of APP, to which both oAb and oTau can bind, causes a marked reduction of the
oligomer entrance into neurons. Most importantly, we have found a common mechanism of action
for extracellular Ab and Tau oligomers, whose deleterious effect on LTP and memory depends upon
the presence of endogenous APP.
Our finding that extracellular oAb requires APP to impair synaptic plasticity and memory is consis-
tent with previous studies showing that Ab neurotoxicity might be mediated by APP, as suggested
by the reduced vulnerability towards Ab of cultured APP null neurons or mutated APP cells
(Lorenzo et al., 2000; Shaked et al., 2006). This finding is also consistent with the observation that
the presence of APP is likely to contribute to hippocampal hyperactivity, which has been suggested
as a key mechanism of disease etiopathogenesis both in AD animal models and patients
Figure 4 continued
KO mice. ANOVA for repeated measures (day 2) F(3,34) = 11.309, p<0.0001. WT + vehicle vs. WT + oTau: § p<0.005 for block 8, and # p<0.001 for block
9 and 10. WT + vehicle: n = 11, WT + oTau: n = 12, APP-KO + vehicle: n = 7, APP-KO + oTau: n = 8. (E–F) Testing with the visible platform task for
assessment of visual-motor-motivational deficits for animals shown in D did not reveal any difference in average speed [ANOVA: F(3,34) = 1.532,
p=0.224] (E) and time to reach the visible platform [ANOVA for repeated measures: F(3,34) = 0.221, p=0.881] (F) among the four groups. (G–H) Open
field testing for the same animals as in D showed a similar percentage of time spent in the center compartment [ANOVA for repeated measures F(3,34)
= 0.190, p=0.902] (G) and the number of entries into the center compartment [ANOVA for repeated measures F(3,34) = 0.354, p=0.787] (H) in vehicle-
and oTau-infused APP-KO mice as well as vehicle- and oTau-infused WT littermates, indicating that they had no differences in exploratory behavior.
DOI: 10.7554/eLife.26991.012
The following source data is available for figure 4:
Source data 1. Data relating to Figure 4A–B–C.
DOI: 10.7554/eLife.26991.013
Source data 2. Data relating to Figure 4D–E–F.
DOI: 10.7554/eLife.26991.014
Source data 3. Data relating to Figure 4G–H.
DOI: 10.7554/eLife.26991.015
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Figure 5. APP is necessary for extracellular oAb and oTau to reduce LTP. (A) Basal synaptic transmission (BST) at the CA3-CA1 connection in slices from
3- to 4-month-old APP-KO mice was similar to WT littermates (n = 18 slices from WT vs. 18 slices from APP-KO; ANOVA for repeated measures F(1,34) =
0.416, p=0.524). (B) LTP was impaired in hippocampal slices from WT mice perfused with oAb (200 nM), whereas there was no impairment in slices from
APP-KO littermates. ANOVA for repeated measures F(3,30) = 19.738, p<0.0001. WT + vehicle vs. WT + oAb: F(1,16) = 29.393, p<0.0001. WT + vehicle vs.
APP-KO + oAb: F(1,13) = 3.297, p=0.093. WT + vehicle: n = 9, WT + oAb: n = 9, APP-KO + vehicle: n = 10, APP-KO + oAb: n = 6. (C) LTP was impaired
in hippocampal slices from WT mice perfused with oTau (100 nM), whereas there was no impairment in slices from APP-KO littermates. ANOVA for
repeated measures F(3,35) = 11.033, p<0.0001. WT + vehicle vs. WT + oTau: F(1,16) = 50.543, p<0.0001. WT + vehicle vs. APP-KO + oTau: F(1,16) = 0.382,
p=0.575. WT + vehicle: n = 8, WT + oTau: n = 10, APP-KO + vehicle: n = 11, APP-KO + oTau: n = 10. (D) CA3-CA1 BST in slices from 3- to 4-month-old
BACE1-KO mice was similar to WT littermates (n = 24 slices from WT vs. 26 slices from BACE-KO; ANOVA for repeated measures F(1,48) = 0.714,
p=0.402). (E) LTP was impaired in hippocampal slices from both WT and BACE-KO mice perfused with oAb (200 nM). ANOVA for repeated measures
F(3,29) = 5.738, p=0.003. WT + vehicle vs. WT + oAb: F(1,14) = 23.663, p<0.0001. WT + vehicle vs. BACE-KO + oAb: F(1,14) = 38.295, p<0.0001. WT +
vehicle: n = 8, WT + oAb: n = 8, BACE-KO + vehicle: n = 9, BACE-KO + oAb: n = 8. F) LTP was impaired in hippocampal slices from both WT and
BACE-KO mice perfused with oTau (100 nM). ANOVA for repeated measures F(3,30) = 6.919, p=0.001. WT + vehicle vs. WT + oTau: F(1,14) = 33.230,
p<0.0001. WT + vehicle vs. BACE-KO + oTau: F(1,15) = 36.9961, p<0.0001. WT + oTau: n = 8, BACE-KO + oTau: n = 9. G) LTP was impaired in
hippocampal slices from both WT and APP-KO mice perfused with oAmy (200 nM). ANOVA for repeated measures F(3,38) = 8.900, p<0.0001. WT +
vehicle vs. WT + oAmy: F(1,21) = 34.694, p<0.0001. WT + vehicle vs. APP-KO + oAmy: F(1,19) = 19.277, p<0.0001. WT + vehicle: n = 11, WT + oAmy:
n = 12, APP-KO + vehicle: n = 9, APP-KO + oAmy: n = 10.
DOI: 10.7554/eLife.26991.016
The following source data is available for figure 5:
Source data 1. Data relating to Figure 5A.
DOI: 10.7554/eLife.26991.017
Source data 2. Data relating to Figure 5B.
DOI: 10.7554/eLife.26991.018
Source data 3. Data relating to Figure 5C.
DOI: 10.7554/eLife.26991.019
Source data 4. Data relating to Figure 5D.
DOI: 10.7554/eLife.26991.020
Source data 5. Data relating to Figure 5E.
DOI: 10.7554/eLife.26991.021
Source data 6. Data relating to Figure 5F.
DOI: 10.7554/eLife.26991.022
Source data 7. Data relating to Figure 5G.
DOI: 10.7554/eLife.26991.023
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(Bakker et al., 2012; Busche et al., 2012; Palop et al., 2007; Verret et al., 2012; Vossel et al.,
2013). Along with these studies, APP has been demonstrated to bind Ab monomers and dimers
leading to activity-dependent APP-APP conformational changes that enhance neurotransmitter
release (Fogel et al., 2014). When Ab is accumulating in the brain, this increase of release probabil-
ity might induce hippocampal hyperactivity resulting in failure of synaptic plasticity and memory loss
(Koppensteiner et al., 2016).
Another interesting finding in our studies is that extracellular oTau requires APP to impair synap-
tic plasticity and memory. In support of this observation a few studies published several years ago,
prior to the introduction of the concept of Tau oligomers, supported a direct interaction between
APP and Tau (Giaccone et al., 1996; Islam and Levy, 1997; Smith et al., 1995). Moreover, recently,
APP has been involved in the uptake of Tau fibrils into cells influencing Tau intracellular aggregation
and spreading in the brain (Takahashi et al., 2015).
The dependence for the presence of APP shared by both oAb and oTau in order to impair synap-
tic plasticity, suggests that APP is a key molecule involved in a common mechanism by which extra-
cellular oAb and oTau interfere with second messenger cascades relevant to memory formation.
Indeed, Ab and Tau share numerous biochemical characteristics and previous studies have sug-
gested a possible common toxicity mechanism (Gendreau et al., 2013). Both peptides are b-sheet
forming proteins, which explains their propensity for oligomerization and close association with
membrane. Furthermore, both peptides can bind APP, a protein with structural similarities to type I
transmembrane receptors, that might act as a cell surface receptor.
APP is also the precursor of Ab (Mu¨ller and Zheng, 2012), which derives from sequential cleav-
age by g- and b-secretases. We have therefore asked whether the toxicity of extracellular Ab and
Tau oligomers depends upon this amyloidogenic processing of APP. To this end we have used mice
deficient in BACE1, the enzyme that initiates the amyloidogenic cascade. We found that BACE1-
deficient mice are susceptible to the synapto-toxicity of oAb and oTau in a similar fashion as WT lit-
termates. Thus, amyloidogenic APP cleavage is not required for the impairment of LTP by the
oligomers.
We also found that the APP dependence for the negative effect of oAb and oTau onto LTP is spe-
cific to these proteins. This observation is consistent with the fact that both proteins are involved in
AD. This conclusion derived from the experiments in which oAmy was capable of reducing LTP in
APP-KO slices. Nevertheless, one cannot exclude that other b-sheet forming proteins besides Ab
and Tau require APP to impair synaptic plasticity. Regardless, the finding that Ab and Tau share APP
as a common mechanism for impairing LTP and memory is relevant and provides a common etiopa-
thogenetic mechanism for their involvement in AD.
Our data are consistent with the hypothesis that APP serves as a common, direct molecular target
for extracellular oAb and oTau to impair LTP and memory. This is supported by the demonstration
that both oAb and oTau bind to APP. However, our experiments do not conclusively demonstrate
that oligomer binding to APP is the cause of LTP and memory reduction, nor we can rigorously
exclude the possibility that the two types of oligomers act on additional targets. For instance, it has
been demonstrated that heparan sulfate and heparin sulphate proteoglycans bind with Ab and Tau
(Holmes et al., 2013; Lindahl et al., 2009) and mediate their internalization and neurotoxicity
(Holmes et al., 2013; Mirbaha et al., 2015; Sandwall et al., 2010). Given that APP and heparan sul-
fate proteoglycans are likely to interact at the plasma membrane (Reinhard et al., 2013) and proteo-
glycans are rapidly degraded in the absence of proteins belonging to the APP superfamily
(Cappai et al., 2005) proteoglycan degradation in the absence of APP might block the toxic action
of oAb and oTau. Nevertheless, the main observation of this manuscript showing that extracellular
oAb and oTau disrupt molecular mechanisms of synaptic plasticity and memory via APP is clear and
has relevant implications for understanding AD etiopathogenesis.
We have found that suppression of APP reduces oAb and oTau entrance into cells. This observa-
tion combined with the finding that intracellular perfusion with 6E10 antibodies recognizing the
sequence 1–16 of human Ab42, rescues the LTP block by extracellular human oAb (Ripoli et al.,
2014), supports the hypothesis that, at least for oAb, APP-dependent uploading of extracellular
oligomers plays a critical role the impairment of synaptic plasticity, and presumably memory. APP
might permit the entrance of the peptides into cells either directly into the cytosol or within vesicles
during endocytosis, after which molecular mechanisms of learning and memory are impaired. A
direct entrance into the cytosol might occur if APP functions as a channel through which the two
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oligomers both with a diameter in the low nm range (Cizas et al., 2010; Fa´ et al., 2016) enter cells.
In agreement with this hypothesis, it has been reported that APP forms a non-selective channel
when injected in Xenopus oocytes (Fraser et al., 1996). A variant on this hypothesis is that APP per-
mits the formation of pores/channels by the oligomers, as ion conductance across lipid bilayers is
increased by oligomers of several different amyloids (Kayed et al., 2004), which affect the perme-
ability of the plasma membrane, leading to elevation of intracellular [Ca2+] and toxic changes. With
this regard, Ab has been reported to form large conductance, non-specific ion channels
(Fraser et al., 1997). The endocytotic mechanism, in turn, is supported by the demonstration that
full-length APP is a transmembrane protein, which is endocytosed from the cell surface into endo-
somes (Nordstedt et al., 1993) and by studies showing endocytosis of Tau (Wu et al. 2013).
Another aspect of our experiments is that APP suppression does not appear to dramatically affect
the number of MAP2-positive cells taking up Ab (only ~80% of WT cells), but does reduce the num-
ber of intracellular aggregates for the peptide per neuron (~55% of WT cells), whereas APP suppres-
sion clearly affects both the number of cells taking up Tau (~50%) and the number of intracellular
aggregates for oTau (~52%). These findings open the question of whether the number of cells taking
up oligomers and the amount of intracellular aggregates may reflect two different processes, i.e.,
uptake and degradation/clearance of aggregates. This is an interesting possibility that might explain
our observations. Of note, to date there is no data showing that APP is involved in modulation of
Ab/Tau clearance. Nevertheless, it would be interesting in future experiments to explore whether
mechanisms controlling protein degradation/clearance in neurons are regulated by APP.
Albeit the experiments on oligomer entrance support the hypothesis that APP serves as a Trojan
horse for oAb and oTau to enter neurons prior to impairing second messenger cascades relevant to
synaptic plasticity and memory formation, they do not exclude an alternative scenario in which oligo-
mer interaction with APP activates the intracellular segment of APP, AID/AICD, triggering a cascade
of events leading to derangement of memory mechanisms. In support of this hypothesis, it has been
shown that phosphorylation of the intracellular threonine 668 of APP mediates synaptic plasticity
deficits and memory loss (Lombino et al., 2013). Moreover, the AID/AICD fragment of APP could
form a multimeric complex with the nuclear adaptor protein Fe65 and the histone acetyltransferase
Tip60, potentially stimulating transcription (Cao and Su¨dhof, 2001). If so, the entrance of the
oligomers might serve other purposes rather than impairing synaptic plasticity and memory. For
instance, it has been suggested that Tau entrance leads to propagation of Tau misfolding
(Frost et al., 2009). Nevertheless, our findings that APP is necessary for impairment of LTP and
memory following elevation of Ab and Tau is still relevant, as it sheds light into how the oligomers
cause memory loss in AD and other neurodegenerative disorders.
The prevailing hypothesis in the AD field is that Ab triggers Tau pathology. Our data, however,
do not support this hypothesis in which Ab and Tau are placed in series but suggest a different sce-
nario in which extracellular Ab and Tau oligomers act in parallel, both through APP. Interestingly,
this hypothesis would also explain why tauopathies result in neuronal loss similar to AD but in the
absence of Ab. The identification of the common biochemical neuronal modifications occurring after
the APP involvement and underlying the derangement of the molecular mechanisms of gene tran-
scription involved in memory formation, is beyond the scope of the present manuscript. Neverthe-
less, our findings are translationally significant, as they have permitted the identification of a
common molecule, APP, which might be therapeutically targeted at sites serving for direct interac-
tion with Ab and Tau oligomers or, alternatively, with proteins downstream of such oligomers, other
than the classical b- and g-secretase sites.
Materials and methods
Animals
All protocols involving animals were approved by Columbia University (#AC-AAAO5301), Universita`
di Catania (#327/2013-B, #119–2017-PR), Universita` Cattolica del Sacro Cuore (#626–2016-PR),
Albert Einstein College of Medicine (#20160407), and the respective Institutional Animal care and
Use Committee (IACUC); experiments involving animals were performed in accordance with the rele-
vant approved guidelines and regulations. C57BL/6J (RRID:IMSR_JAX:000664) and App-KO (Jackson
Lab B6.129S7-Apptm1Dbo/J; RRID:IMSR_JAX:004133) mice and their littermates were obtained
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from breeding colonies kept in the animal facility of Columbia University, Universita` di Catania, and
Universita` Cattolica del Sacro Cuore. Bace1-KO mice (Luo et al., 2001) and their WT littermates
were obtained from a breeding colony kept at Albert Einstein College of Medicine which derived
from mice that were originally donated by Dr. Vassar at Northwestern University. They were 3–4
months of age except newborn mice for cell cultures. Both sexes were used. All mice were main-
tained on a 12 hr light/dark cycle (lights on at 6:00 AM) in temperature and humidity-controlled
rooms; food and water were available ad libitum.
Oligomer preparation
Tau oligomers
Human Tau preparation and oligomerization was obtained as described previously with slight modifi-
cations (Fa´ et al., 2016). Briefly, a recombinant Tau 4R/2N construct containing C-terminal 6x His-
tag was transfected in Escherichia coli (Rosetta). Cells were streaked on LB agar ampicillin plates and
a single colony was picked and grown overnight in a shaker at 37˚C in 100 ml Expansion Broth
(Zymo Research) and 300 ml Overexpression Broth (Zymo Research). Cells were pelleted at 4 ˚C by
centrifugation at 6000  g. After a freeze-thaw cycle, cells were lysed in a 2% Triton X-100 PBS and
with a protease inhibitor mixture (Complete, EDTA-free; Roche Diagnostics). Streptomycin sulfate
was added to precipitate DNA. After incubation for 5 min at 4˚C followed by sonication, the prepa-
ration was heated at 100˚C for 15 min, and centrifuged to remove the precipitate. TCEP-HCl (Ther-
moScientific) and 1% perchloric acid were added to the supernatant prior to neutralizing it with 1N
NaOH, and placing it in a Pierce protein concentrator (PES, 30K MWCO) (ThermoScientific) to be
centrifuged at 4000  g. The resulting supernatant was loaded on His-Spin Protein Miniprep col-
umns (Zymo Res.) and eluted with phosphate buffer containing 300 mM NaCl plus 250 mM imidaz-
ole. Eluted tau was then treated with TCEP-HCl and EDTA, and incubated at room temperature (RT)
for 1 hr. Oligomerization buffer was next added to the treated eluted Tau prior to centrifuging it in
a PES at 4000  g. Oligomerization was achieved via introduction of disulfide bonds through incuba-
tion with 1 mM H2O2 at room RT for 20 hr, followed by centrifugation in a PES at 4000  g. The
resulting material was used for our experiments. Tau protein concentration was determined from the
absorption at 280 nm with an extinction coefficient of 7450 cm 1 M 1.
Ab oligomers
Human Ab42 oligomerization was obtained as described previously (Puzzo et al., 2005;
Watterson et al., 2013). Briefly, a protein film was prepared by dissolving Ab42 lyophilized powder
(Biopolymer Laboratory, UCLA, CA, USA or American Peptide, CA, USA) in 1,1,1,3,3,3-Hexafluoro-2-
Propanol (HFIP) and subsequent incubation for 2 hr at RT to allow complete monomerization. The
Ab film was dissolved in dimethylsulfoxide (DMSO), sonicated for 15 min, aliquoted, and stored at
 20˚C. To oligomerize the peptide, phosphate buffered saline (PBS) was added to an aliquot of
DMSO-Ab to obtain a 5 mM solution that was incubated for 12 hr at 4˚C. This oligomerized Ab solu-
tion was then diluted to the final concentration of 200 nM in artificial cerebrospinal fluid (ACSF) com-
posed as following: 124.0 NaCl, 4.4 KCl, 1.0 Na2HPO4, 25.0 NaHCO3, 2.0 CaCl2, 2.0 MgCl2 in mM.
Amylin oligomers
Human Amy oligomerization was obtained as described previously (Ripoli et al., 2014). Briefly, a
protein film was prepared by dissolving Amy lyophilized powder (Anaspec, CA, USA) in HFIP and
subsequent incubation for 2 hr at RT to allow complete monomerization. The Amy film was dissolved
in DMSO, sonicated for 15 min, aliquoted, and stored at  20˚C. To oligomerize the peptide, PBS
was added to an aliquot of DMSO-Amy to obtain a 5 mM solution that was incubated for 12 hr at
4˚C. This oligomerized Amy solution was then diluted to the final concentration of 200 nM in ACSF.
Co-Immunoprecipitation
WT and APP695 with the Swedish mutation (APPSw) overexpressing human embryonic kidney
(HEK293; RRID:CVCL_0045) cells were used to examine the molecular interaction between Tau
oligomers and APP. HEK293 cells were originally obtained from ATCC and verification of the cell
line was validated by STR profiling (see; https://www.atcc.org/Products/All/CRL-1573.aspx#specifica-
tions). Testing for potential mycoplasma was performed using Hoechst 33258 as a marker for
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indirect DNA fluorescent staining (protocol described at: http://www.sigmaaldrich.com/technical-
documents/protocols/biology/testing-for-mycoplasma0.html).
APPSw and untransfected cells were maintained in DMEM supplemented with 10% fetal bovine
serum. Membrane fractions were prepared by homogenizing cells in buffer (5 mM HEPES pH 7.4, 1
mM EDTA, 0.25 M sucrose, protease inhibitor cocktail). Extracts were clarified by centrifugation
(1000  g, 5 min, 4˚C) and membrane fractions were obtained by centrifuging supernatant (100,000
 g, 1 hr, 4˚C). Membranes from control (endogenous APP only) and APPSw expressing cells were
solubilized under mild conditions (25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% CHAPSO,
protease inhibitor cocktail), diluted to 0.5% CHAPSO - to maintain normal lipidation of APP and
native protein conformation - and incubated with Tau 4R/2N oligomers (10 mg, 3–4 hr, 4˚C). Samples
(1.11 mg total protein) were incubated with a monoclonal antibody directed to the APP C-terminal
domain (C1/6.1 Mathews et al., 2002); 5 mg, 2 hr) and immunoprecipitated using Protein G-Sephar-
ose. Non-specific bound proteins were removed by successive washing with lysis buffer. Immunopre-
cipitated APP complexes were eluted with Laemmli buffer, resolved by SDS-PAGE (4–12% Bis-Tris
gels, BioRad) and probed for Tau using Tau-5 antibodies (1:1,000) and APP-CTF (C1/6.1) to confirm
the immunoprecipitation efficiency as well as the interaction.
Far western blotting (fWB)
APP-Tau interaction was detected performing fWB as previously described (Wu et al., 2007). Hippo-
campal neurons were lysed in cold RIPA buffer containing 1 mM phenylmethylsulfonyl fluoride, phos-
phatase and protease inhibitor mixtures (Sigma) and 0.1% sodium dodecyl sulfate. After incubation
for 30 min on ice and centrifugation (10,000  g for 30 min at 4˚C), the supernatant was removed
and protein concentration was determined using the Bio-Rad protein assay. Each protein sample (30
mg) was separated on 8% SDS-polyacrylamide gel and blotted onto nitrocellulose membranes (Milli-
pore Co., Bedford, MA). The blotted proteins were then denatured with guanidine–HCl and then
renatured by gradually reducing guanidine concentration (from 6 to 0 M). The last renaturing step
with the guanidine-HCl-free buffer was maintained overnight at 4˚C. The membrane was blocked
with 5% nonfat dry milk in TBS, 1% tween-20 (TBST) for 1 hr at RT and then incubated overnight at
4˚C with 10 mg of purified ‘bait’ protein oTau. After three washes with TBST, the membrane was
incubated with one of the following primary antibodies for 1 hr a RT in 3% milk in the TBST buffer:
anti Tau Ab-2 (clone Tau-5, Thermo Fisher Scientific, Waltham, MA). Membranes were then stripped
by heating at 56˚C in 62.5 mM Tris-HCl, pH 6.7, with 100 mM 2-mercaptoethanol and 2% SDS and
re-incubated with anti APP-C terminus (Sigma) to check whether Tau and APP are on the same posi-
tion on the membrane. Blots were developed with the Pierce ECL Plus Western Blotting Substrate
(Thermo Fisher Scientific) and visualized using UVItec Cambridge Alliance. The BenchMark Pre-
Stained Protein Ladder (Invitrogen) was used as molecular mass standards.
Assessment of oligomers entrance into neurons
Primary hippocampal neuronal cultures
Primary cultures of hippocampal neurons were obtained from C57BL/6J mice (WT), and B6.129S7-
Apptm1Dbo/J (APP KO) mice as previously described (Piacentini et al., 2015; Scala et al., 2015).
Briefly, hippocampi dissected from the brain of E18 mice embryos were incubated for 10 min at
37˚C in PBS containing trypsin-ethylenediaminetetraacetic acid (0.025%/0.01% wt/vol; Biochrom AG,
Berlin, Germany), and the tissue was then mechanically dissociated at RT with a fire-polished Pasteur
pipette. The cell suspension was harvested and centrifuged at 235  g for 8 min. The pellet was sus-
pended in 88.8% Minimum Essential Medium (Biochrom), 5% fetal bovine serum, 5% horse serum,
1% glutamine (2 mM), 1% penicillin-streptomycin-neomycin antibiotic mixture (Invitrogen, Carlsbad,
CA), and glucose (25 mM). Cells were plated at a density of 105 cells on 20 mm coverslips (for immu-
nocytochemical studies) and 106 cells/well on 35 mm six-well plates (for fWB studies), precoated
with poly-L-lysine (0.1 mg/mL; Sigma, St. Louis, MO). Twenty-four hours later, the culture medium
was replaced with a mixture of 96.5% Neurobasal medium (Invitrogen), 2% B-27 (Invitrogen), 0.5%
glutamine (2 mM), and 1% penicillin streptomycin- neomycin antibiotic mixture. After 72 hr, this
medium was replaced with a glutamine free version of the same medium, and the cells were grown
for 10 more days before experiments.
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Preparation of labeled Ab
Freeze-dried human synthetic Ab42 labeled with HiLyteTM Fluor 555 at the C-terminus (oAb 555)
was purchased from AnaSpec (Fremont, CA). Protein solution was prepared as previously described
(Ripoli et al., 2013). Briefly, peptide was diluted to 1 mM in 1,1,1,3,3,3,-hexafluoro-2-propanol to
disassemble preformed aggregates and stored as dry films at  20˚C before use. The film was dis-
solved at 1 mM in DMSO, sonicated for 10 min, diluted to 100 mM in cold PBS, and incubated for 12
hr at 4˚C to promote protein oligomerization. Ab42-555-labeled preparation was purified with Ami-
con Ultra Centrifugal Filter (2 KDa) and then was resuspended in PBS at a concentration of 100 mM
before final dilution in the culture medium.
Preparation of labeled Tau
oTau preparations were labeled with the IRIS-5-NHS active ester dye (IRIS-5; lex: 633 nm; lem:
650–700 nm; Cyanine Technology Turin, Italy) as previously described (Fa´ et al., 2016). Briefly, Tau
solutions (2 mM in PBS) were mixed with 6 mM IRIS-5 in DMSO for 4 hr in the dark under mild shak-
ing conditions. After this time, labeled Tau was purified with Vivacon 500 ultrafiltration spin columns
(Sartorius Stedim Biotech GmbH) and then resuspended in PBS and used at final concentration of
100 nM in the culture medium.
Assessment of oAb and oTau entrance into neurons
WT and APP KO hippocampal neurons at 14 days in vitro were treated with either 200 nM Ab42-555
or 100 nM oTau-IRIS5 for 20 min. After treatment cells were fixed with 4% paraformaldehyde in PBS
for 10 min at RT, permeabilized for 15 min with 0.3% Triton X-100 [Sigma] in PBS, and incubated for
30 min with 0.3% BSA in PBS to block nonspecific binding sites. The primary antibody rabbit anti
microtubule associated protein 2 (MAP2, Immunological Sciences, Rome, Italy; 1:200 overnight at
4˚C for 90 min) and the corresponding secondary antibody Alexa Fluor 488 donkey anti-rabbit (Invi-
trogen 1:1000 for 90 min at RT) were then used to recognize neurons. Nuclei were counterstained
with 40,6-diamidino-2-phenylindole (DAPI, 0.5 mg/ml for 10 min; Invitrogen) and cells were cover-
slipped with ProLong Gold anti-fade reagent (Invitrogen), before being studied through high-resolu-
tion confocal microscopy. Confocal stacks made of images (512  512 pixels) were acquired with a
confocal laser scanning system (Nikon A1 MP) and an oil-immersion objective (60 magnification; N.
A. 1.4). Additional 2.5 magnification was applied to obtain a pixel size of 90 nm. Fluorescent dyes
were excited with diode lasers (405, 488, 546 and 633 nm). The following criteria were used for spot
detection: XY area 200 nm2; Z height 1.5 mm. The studied proteins were considered internalized
when the overlapping of MAP2 fluorescence with the height of the fluorescent spots was greater
than 65% (~1 mm). Conversely, they were considered attached to the neuronal surface when the fluo-
rescence signals were close to each other, but with less than 30% overlap. Spots internalized in neu-
rons were detected and counted by the Image J software, through an algorithm that automatically
detects co-localization between MAP2 fluorescence and either Ab555 or Tau-IRIS5. MAP2 fluores-
cence was binarized to form a mask of the fluorescence pattern for every single XY plane of the Z
stacks, and this mask was multiplied plane-by-plane for the corresponding fluorescence of Ab or Tau
stacks. This operation selected only Ab and Tau signals associated with MAP2-positive areas by
deleting any Ab and Tau signals unrelated to MAP-2 immunoreactivity. The resulting fluorescence
signals gave an unbiased estimate of Ab or Tau oligomers internalized in neurons within each micro-
scopic field. The number of fluorescent spots were then counted by the ‘analyze particle’ macro of
Image J after having done a maximum intensity projection of every Z stacks. To provide a global
estimate of the protein uploading into neurons, internalization of oAb and oTau was also quantified
through the ‘internalization index’ obtained by multiplying the percentage of neurons internalizing
fluorescent proteins by the mean number of fluorescent spots inside neurons. Assessment of fluores-
cent protein oligomers attached to the neuronal surface was carried out by spanning the XZ-YZ
planes from Z stacks for every microscopic field acquired.
Behavioral studies
Intrahippocampal administration of oAb and oTau
To perform intrahippocampal infusions of oligomers, mice underwent stereotaxic surgery for cannu-
las implantation. After anesthesia with Avertin (500 mg/Kg), mice were implanted with a 26-gauge
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guide cannula into the dorsal part of the hippocampi (coordinates from bregma: posterior = 2.46
mm, lateral = 1.50 mm to a depth of 1.30 mm). After 6–8 days of recovery, mice were bilaterally
infused with oAb or oTau preparations or vehicle in a final volume of 1 ml over 1 min with a microsyr-
inge connected to the cannulas via polyethylene tubing. During infusion, animals were handled
gently to minimize stress. After infusion, the needle was left in place for another minute to allow dif-
fusion. In some animals, after behavioral studies, a solution of 4% methylene blue was infused for
localization of infusion cannulas.
Fear conditioning
Fear conditioning was performed as previously described (Fiorito et al., 2013; Watterson et al.,
2013). Our conditioning chamber, equipped with a camera placed on the top of the cage, was in a
sound-attenuating box. The conditioning chamber had a bar insulated shock grid floor, removable.
After each experimental test the floor was cleaned with 75% ethanol. Mice were handled once a day
for 3 days before behavioral experiments. Only one animal at a time was present in the experimenta-
tion room. During the first day, mice were placed in the conditioning chamber for 2 min before the
onset of a discrete tone [conditioned stimulus (CS)] (a sound that lasted 30 s at 2800 Hz and 85 dB).
In the last 2 s of the CS, mice were given a foot shock [unconditioned stimulus (US)] of 0.80 mA for 2
s through the bars of the floor. After the CS/US pairing, the mice were left in the conditioning cham-
ber for 30 s and then they were placed back in their home cages. Freezing behavior, defined as the
absence of all movement except for that necessitated by breathing, was manually scored. During
the second day, we evaluated the contextual fear learning. Mice were placed in the conditioning
chamber and freezing was measured for five consecutive min. During the third day, we evaluated
the cued fear learning. Mice were placed in a novel context (rectangular black cage with vanilla
odorant) for 2 min (pre-CS test), after which they were exposed to the CS for 3 min (CS test), and
freezing was measured. Sensory perception of the shock was determined 24 hr after the cued test
through threshold assessment. Foot shock intensity started at 0.1 mA and increased by 0.1 mA every
30 s. We recorded the first visible, motor and vocal response.
2 day radial arm water maze (RAWM)
RAWM was performed as previously described (Watterson et al., 2013). During the first day, mice
were trained in 15 trials to identify the platform location in a goal arm by alternating between a visi-
ble and a hidden platform from trial 1 to 12 (beginning with the visible platform in the assigned
arm). In the last four trials (trial 13–15) only a hidden platform was utilized. During the second day
the same procedure was repeated by using only the hidden platform from trial 1 to 15. An entrance
into an arm with no platform, or failure to select an arm after 15 s was counted as an error and the
mouse was gently pulled back to the start arm. The duration of each trial was up to 1 min. At the
end of each trial, mouse rested on the platform for 15 s. The goal arm was kept constant for all trials,
with a different starting arm on successive trials. Data were analyzed and displayed as averages of
blocks of 3 trials per mouse. A visible platform test was performed to control for possible motiva-
tional, visual and motor deficits. This consisted in a two-day test, with two sessions/day (each consist-
ing of three 1 min trials), in which we recorded the time taken to reach a visible platform (randomly
positioned in a different place each time) marked with a green flag.
Open field
Open Field was performed as previously described (Fa´ et al., 2016). Our arena consisted in a white
plastic bow divided into sectors (periphery and center) by black lines. Each mouse started the test
randomly from one of the border, and was permitted to freely explore the arena for 5 min in two
consecutive days. The test was performed in a quiet, darkened room and one light bulb provided a
bright illumination. We scored the % time spent into the center and the number of entries into the
center.
Electrophysiological recordings
Electrophysiological recordings were performed as previously described (Puzzo et al., 2005). Briefly,
transverse hippocampal slices (400 mm) were cut and transferred to a recording chamber where they
were maintained at 29˚C and perfused with ACSF (flow rate 2 ml/min) continuously bubbled with
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95% O2 and 5% CO2. Field extracellular recordings were performed by stimulating the Schaeffer col-
lateral fibers through a bipolar tungsten electrode and recording in CA1 stratum radiatum with a
glass pipette filled with ACSF. After evaluation of basal synaptic transmission, a 15 min baseline was
recorded every minute at an intensity eliciting a response approximately 35% of the maximum
evoked response. LTP was induced through a theta-burst stimulation (4 pulses at 100 Hz, with the
bursts repeated at 5 Hz and three tetani of 10-burst trains administered at 15 s intervals). Responses
were recorded for 2 hr after tetanization and measured as field excitatory post-synaptic potentials
(fEPSP) slope expressed as percentage of baseline.
Statistical analyses
All experiments were in blind with respect to treatment. All data were expressed as mean ± standard
error mean (SEM). For experiments on oligomer entrance into cultured neurons pairwise compari-
sons were performed through Student’s t test. Behavioral experiments were designed in a balanced
fashion and, for each condition mice were trained and tested in three to four separate sets of experi-
ments. Freezing, latency, time spent in the center of the arena and number of entries in the center
were manually scored by an expert operator by using a video-tracking recording system. We used
one-way ANOVA with Bonferroni post-hoc correction or ANOVA with repeated measures for com-
parisons among the four groups of mice. For electrophysiological recordings on slices, results were
analyzed in pClamp 10 (Molecular Devices; RRID:SCR_011323) and compared by ANOVA with
repeated measures considering 120 min of recording after tetanus or the 26th-30th recording
points. Statistical analysis was performed by using Systat 9 software (Chicago, IL, USA; RRID:SCR_
010455). For protein entrance into neurons we used Student’s t-test to compare the internalization
index between WT and APP KO neurons. The level of significance was set at p<0.05.
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